Thus, our results suggest that genetic alterations or an altered expression of CSF3R may serve as a risk factor in SCLC development and associate with the autophagy pathway, while FavId could serve as a potential drug therapy through the CSF3R target to treat SCLC, even though additional in vivo or in vitro studies are needed to clarify these associations in SCLC. This evidence concerns the gene CSF3R and small cell lung carcinoma.